PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Incyte Corporation (INCY)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US45337C1027

CUSIP

45337C102

Sector

Healthcare

IPO Date

Nov 4, 1993

Highlights

Market Cap

$11.31B

EPS (TTM)

$0.15

PE Ratio

389.73

PEG Ratio

0.37

Total Revenue (TTM)

$3.36B

Gross Profit (TTM)

$3.09B

EBITDA (TTM)

$149.62M

Year Range

$50.35 - $83.95

Target Price

$73.35

Short %

6.58%

Short Ratio

3.42

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
INCY vs. SMH INCY vs. SPY INCY vs. PDD INCY vs. ILMN INCY vs. HOLX INCY vs. GILD
Popular comparisons:
INCY vs. SMH INCY vs. SPY INCY vs. PDD INCY vs. ILMN INCY vs. HOLX INCY vs. GILD

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Incyte Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


1,000.00%2,000.00%3,000.00%4,000.00%NovemberDecember2025FebruaryMarchApril
3,017.87%
1,079.62%
INCY (Incyte Corporation)
Benchmark (^GSPC)

Returns By Period

Incyte Corporation had a return of -15.36% year-to-date (YTD) and 9.41% in the last 12 months. Over the past 10 years, Incyte Corporation had an annualized return of -5.40%, while the S&P 500 had an annualized return of 10.02%, indicating that Incyte Corporation did not perform as well as the benchmark.


INCY

YTD

-15.36%

1M

-13.85%

6M

-11.81%

1Y

9.41%

5Y*

-9.41%

10Y*

-5.40%

^GSPC (Benchmark)

YTD

-8.25%

1M

-4.30%

6M

-7.20%

1Y

6.61%

5Y*

14.07%

10Y*

10.02%

*Annualized

Monthly Returns

The table below presents the monthly returns of INCY, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20257.37%-0.89%-17.62%-3.45%-15.36%
2024-6.40%-0.70%-2.38%-8.64%11.03%4.90%7.34%0.91%0.67%12.13%0.63%-7.40%10.00%
20236.00%-9.58%-6.12%2.96%-17.28%1.14%2.36%1.27%-10.48%-6.65%0.76%15.55%-21.83%
20221.27%-8.11%16.28%-5.62%1.24%0.11%2.25%-9.33%-5.38%11.55%7.17%0.82%9.43%
20213.18%-12.36%3.32%5.06%-1.87%0.42%-8.06%-1.11%-10.08%-2.62%1.10%8.39%-15.61%
2020-16.32%3.20%-2.89%33.36%4.35%2.02%-5.01%-2.44%-6.86%-3.45%-2.42%2.89%-0.39%
201926.73%7.00%-0.26%-10.71%2.38%8.05%-0.05%-3.65%-9.28%13.05%12.20%-7.26%37.32%
2018-4.67%-5.68%-2.15%-25.67%10.22%-1.86%-0.69%11.08%-6.53%-6.17%-0.88%-1.03%-32.86%
201720.88%9.81%0.43%-7.02%4.06%-2.64%5.86%3.09%-15.04%-2.99%-12.59%-4.32%-5.55%
2016-34.94%4.17%-1.40%-0.28%16.80%-5.25%12.79%-10.10%16.26%-7.76%17.62%-1.97%-7.54%
20159.03%7.70%6.77%6.00%13.37%-5.39%0.07%11.42%-5.04%6.53%-2.80%-5.07%48.34%
201429.41%-1.92%-16.71%-9.27%2.04%13.91%-15.72%13.94%-9.50%36.72%12.66%-3.23%44.40%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of INCY is 62, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of INCY is 6262
Overall Rank
The Sharpe Ratio Rank of INCY is 6666
Sharpe Ratio Rank
The Sortino Ratio Rank of INCY is 5959
Sortino Ratio Rank
The Omega Ratio Rank of INCY is 5959
Omega Ratio Rank
The Calmar Ratio Rank of INCY is 6262
Calmar Ratio Rank
The Martin Ratio Rank of INCY is 6565
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Incyte Corporation (INCY) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for INCY, currently valued at 0.25, compared to the broader market-2.00-1.000.001.002.003.00
INCY: 0.25
^GSPC: 0.28
The chart of Sortino ratio for INCY, currently valued at 0.58, compared to the broader market-6.00-4.00-2.000.002.004.00
INCY: 0.58
^GSPC: 0.53
The chart of Omega ratio for INCY, currently valued at 1.08, compared to the broader market0.501.001.502.00
INCY: 1.08
^GSPC: 1.08
The chart of Calmar ratio for INCY, currently valued at 0.13, compared to the broader market0.001.002.003.004.00
INCY: 0.13
^GSPC: 0.28
The chart of Martin ratio for INCY, currently valued at 0.71, compared to the broader market-5.000.005.0010.0015.0020.00
INCY: 0.71
^GSPC: 1.31

The current Incyte Corporation Sharpe ratio is 0.25. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Incyte Corporation with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.001.002.003.00NovemberDecember2025FebruaryMarchApril
0.25
0.28
INCY (Incyte Corporation)
Benchmark (^GSPC)

Dividends

Dividend History


Incyte Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%NovemberDecember2025FebruaryMarchApril
-61.71%
-12.17%
INCY (Incyte Corporation)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Incyte Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Incyte Corporation was 98.54%, occurring on Mar 9, 2009. Recovery took 2016 trading sessions.

The current Incyte Corporation drawdown is 61.71%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.54%Feb 28, 20002270Mar 9, 20092016Mar 10, 20174286
-67.12%Feb 5, 1998420Oct 5, 199956Dec 23, 1999476
-66.47%Mar 16, 20171790Apr 25, 2024
-41.98%Feb 20, 199749Apr 30, 199795Sep 15, 1997144
-38.89%Feb 11, 199447Apr 20, 1994155Dec 1, 1994202

Volatility

Volatility Chart

The current Incyte Corporation volatility is 12.45%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%NovemberDecember2025FebruaryMarchApril
12.45%
13.54%
INCY (Incyte Corporation)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Incyte Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Incyte Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio
20.040.060.080.0100.0
INCY: 389.7
The chart displays the Price-to-Earnings (P/E) ratio for INCY, comparing it with other companies in the Biotechnology industry. Currently, INCY has a P/E ratio of 389.7. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
2.04.06.08.010.0
INCY: 0.4
The chart shows the Price/Earnings to Growth (PEG) ratio for INCY compared to other companies in the Biotechnology industry. INCY currently has a PEG ratio of 0.4. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
2.04.06.08.010.0
INCY: 2.7
This chart shows the Price-to-Sales (P/S) ratio for INCY relative to other companies in the Biotechnology industry. Currently, INCY has a P/S ratio of 2.7. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
2.04.06.08.010.0
INCY: 3.3
The chart illustrates the Price-to-Book (P/B) ratio for INCY in comparison with other companies in the Biotechnology industry. Currently, INCY has a P/B value of 3.3. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Incyte Corporation.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab